Integra LifeSciences – Limit UncertaintyIntegra LifeSciences (IART) is a multinational provider of medical devices to support a wide range of surgical needs. Their strategic intent is to become the world leader in orthopedic extremity surgery, neurosurgery, spine surgery, and reconstructive and general surgery. Their innovative offerings and growth through acquisitions have enabled them to become a billion-dollar enterprise since their inception in 1989 ("IART Profile"). They are headquartered in Plainsboro, New Jersey and have 3,300 employees worldwide (“Company Profile,” 2014). Integra's common stock is traded on the NASDAQ Stock Market under the symbol "IART." Integra's target markets are in the United States, European Union, Asia Pacific, BRIC (Brazil, Russia, India and China) and Latin America. Integra's business model is divided into extremity support, spine, neurosurgery and international divisions. This allows them to focus on core competencies while responding to local needs. Their broad product portfolio includes orthopedics, implants and hospital equipment used in neurosurgery, neuromonitoring, neurotrauma and related critical care. Integra's primary markets are the United States, where approximately 75% of revenues are generated (“Integra lifesciences reports,” 2014). Integra's growth from 1989 to 2014 was driven using an acquisition model. During this period, Integra completed over 40 acquisitions. This model has limited organic growth as most new product introductions involve derivative improvements of existing products. Their most recent acquisition was their largest. They made a deal with Covidien to acquire DuraSeal for $235 million in… middle of paper… Ant System. Retrieved May 3, 2014, from http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm185478.htmGerber, J. (2011). International economy. (5th ed.). Upper Saddle River, NJ: PrenticeIART profile. (n.d.). . Retrieved May 3, 2014, from http://finance.yahoo.com/q/pr?s=IART+ProfileIntegra LifeSciences Completes Acquisition of DuraSeal Product Lines from Covidien. (January 15, 2014). . Retrieved May 2, 2014, from http://globenewswire.com/news-release/2014/01/15/602722/10064277/en/Integra-LifeSciences-Completes-Acquisition-of-DuraSeal-Product-Lines-From-Covidien. htmlIntegra LifeSciences reports financial results for the first quarter of 2014. (May 1, 2014). MarketWatch. Retrieved May 3, 2014, from http://www.marketwatch.com/story/integra-lifesciences-reports-first-quarter-2014-financial-results-2014-05-01